Merck & Co., Inc.
Financials
Valuation Metrics
Merck & Co., Inc.'s Market Cap is $315.63B. At end of 2025 it was $262.09B. Ranked #39 of 3,112 in US market (top 1%), #21 of 1,667 on NYSE (top 1%), #4 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 1%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $315.63B | US#39/3,112 Sec#4/269 |
| Revenue | $65.59B | US#100/3,112 Sec#3/269 |
| Net Income | $8.94B | US#76/3,112 Sec#8/269 |
| Total Assets | $128.69B | US#139/3,112 Sec#5/269 |
| Net Assets | $45.88B | US#104/3,112 Sec#6/269 |
| Employees | 73,000 | US#116/3,112 Sec#4/269 |
| Value | ||
| P/E | 35.33x | US#1,606/3,112 Sec#51/269 |
| P/B | 6.88x | US#2,406/3,112 Sec#172/269 |
| P/S | 4.81x | US#2,233/3,112 Sec#75/269 |
| EV/EBITDA | 19.14x | US#1,805/3,112 Sec#54/269 |
| FCF Yield | 4.47% | US#1,406/3,112 Sec#50/269 |
| Profitability | ||
| ROE | 19.48% | US#591/3,112 Sec#40/269 |
| ROA | 6.94% | US#745/3,112 Sec#42/269 |
| Op. Margin | 27.59% | US#543/3,112 Sec#27/269 |
| Revenue Growth | 4.27% | US#1,826/3,112 Sec#111/269 |
| Earnings Growth | -183.48% | US#2,215/3,112 Sec#78/269 |
| Financial Health | ||
| Debt Ratio | 180.38% | US#1,683/3,112 Sec#197/269 |
| Total Debt | $49.12B | US#90/3,112 Sec#4/269 |
| FCF | $14.12B | US#46/3,112 Sec#4/269 |
| Cash | $5.33B | US#186/3,112 Sec#11/269 |
| Current Ratio | 1.30x | US#1,871/3,112 Sec#251/269 |
| Net Debt/EBITDA | 2.33x | US#1,474/3,112 Sec#64/269 |
| Dividend | ||
| Div. Yield | 2.61% | US#705/3,112 Sec#12/269 |
| Div. Growth | 5.31% | US#791/3,112 Sec#9/269 |
| Performance | ||
| 1Y Return | 64.16% | US#565/3,112 Sec#106/269 |
| 1M Return | -1.36% | US#1,833/3,112 Sec#89/269 |
| From 52W High | -5.37% | US#597/3,112 Sec#22/269 |
| 1Y MDD | -11.90% | US#123/3,112 Sec#4/269 |
| Trading | ||
| Volume | 8,497,537 shares | US#206/3,112 Sec#14/269 |
| Trading Value | $1.09B | US#87/3,112 Sec#7/269 |
| Per Share | ||
| EPS | $7.33 | US#392/3,112 Sec#12/269 |
| BPS | $21.13 | US#1,151/3,112 Sec#30/269 |
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.